This is the third issue of a monthly index of listed research peptide prices, following the May and June issues.
July had a shape the first two months did not: the largest vendor in the index raised prices across nearly its entire catalog, three vendors cut, and the market as a whole finished the month within a nickel of where it started.
What was measured
Prices are compared listing against listing, between the first week of July and the last. A listing counts only if it was in stock and priced in both.
- Panel: 846 listings, spanning 75 compounds across 19 vendors.
- Prices are raw list prices, before any coupon or site-wide discount.
- Per-milligram figures cover vial and liquid products sold by mass. Capsules, sprays and products dosed by volume are excluded.
Full definitions are on the methodology page.
Prices stayed sticky for a third month
Of the 846 listings, 644 (76%) ended July at exactly the price they started it. That is the third consecutive month in the same band: 78% in May, 88% in June, 76% in July. Whatever else moves in this market, most listed prices sit still for weeks at a time.
Among the 202 listings that did move, 114 fell and 88 rose, and the median mover fell 3.14%.
As of July 31, 2026, the median listed price across the compounds in the index was $4.90 per milligram, against $4.92 a month earlier. Half of all listings fell between $3.00 and $7.00 per milligram.
One vendor raised, three cut
- Peptide Giants, the largest vendor in the index at 82 tracked listings, raised 70 of them by a median of 10.00%. It came as a single catalog-wide repricing rather than gradual drift.
- Ascension Peptides cut 33 of its 38 tracked listings, by a median of 9.20%.
- Oneday Compounds cut all 28 of its tracked listings, by a median of 7.15%.
- Purity Peptides cut all 45 of its tracked listings, by a median of 3.14%.
- Seven of the 19 vendors changed no price at all.
Those four vendors are the month. Everything else was a listing or two at a time, and the two directions came close to cancelling out, which is why the market level barely moved while a quarter of it repriced.
The largest single increase was BPC-157 at Alpha Peptides, up 43.0% from $1.82 to $2.60 per milligram. The largest decrease on a single compound was pinealon at Ascension Peptides, down 37.7% from $8.50 to $5.30 per milligram.
The same compound still costs 3x more at one vendor than another
The gap between the cheapest and most expensive listing of the same compound remains the largest number in this market, and it did not move in July. Among compounds carried by five or more vendors, the median one costs about three times as much at its dearest listing as at its cheapest. That is where it has sat since we began publishing this index.
These are the widest, as of July 31, 2026.
- Retatrutide ranged from $1.25 to $17.00 per milligram across 115 listings from 24 vendors, the widest gap in the index.
- Tirzepatide ranged from $0.87 to $11.00 per milligram across 97 listings from 24 vendors.
- 5-Amino-1MQ ranged from $1.00 to $11.00 per milligram across 30 listings from 19 vendors.
Tirzepatide held the widest gap in both previous issues at 16.5-fold, and no longer does. Its most expensive listings came down over the month, but its cheapest did not.
The FDA vote did not move prices
The PCAC vote of July 23-24, in which an FDA advisory committee recommended six of seven peptides for the 503A compounding list, produced no price response through the end of the month.
Prices on the voted peptides changed about as often as everything else (26.3% of their listings against 23.4% of the rest), and the median change was zero in both groups. That covers six of the seven. The seventh, TB-500, is not the molecule vendors sell under that name, and almost nobody lists the one the panel voted on.
Nothing here rules out a price response later. A recommendation is not a rule, and the rulemaking that would change anything is months away at the earliest.
What this does not measure
- It measures listed prices, not transaction prices. Coupons, first-order discounts and bulk terms are not applied.
- It does not test products, verify purity, or assess any vendor's certificates of analysis.
- Vendor and listing counts describe what this index covers, not the size of the market.
Sources
- PeptideScouter methodology, covering index construction, normalization and known limits.
- PeptideScouter price index, the live per-milligram figures this report is drawn from.
- Peptide Price Index, June 2026, the previous issue.
- What the FDA peptide compounding vote does and does not change, background on the July 23-24 PCAC meeting.
- Underlying data is PeptideScouter's own daily price archive, collected from public vendor storefronts.
All figures in this report are as of July 31, 2026, computed from the archive as of publication.